Exploration of cathepsin S inhibitors characterized by a triazole P1-P2 amide replacement
Neil Moss1, Zhaoming Xiong, Mike Burke
1Department of Medicinal Chemistry, Immunology and Inflammation, Boehringer Ingelheim Pharmaceutical, Inc., 900 Ridgebury Road, Ridgefield, CT 06877, USA. Neil.Moss@comcast.com
Bioorganic & Medicinal Chemistry Letters
|October 23, 2012
Abstract:
This paper details exploration of a class of triazole-based cathepsin S inhibitors originally reported by Ellman and co-workers. SAR studies involving modifications across the whole inhibitor provide a perspective on the strengths and weaknesses of this class of inhibitors. In addition, we put the unique characteristics of this class of compounds into perspective with other classes of cathepsin S inhibitors.


